Present and Future Perspectives on the Role of Biomarkers in Atherosclerotic Cardiovascular Disease Risk Stratification.
作者信息
Gigante Bruna
机构信息
Division of Cardiovascular Medicine, Department of Medicine, Karolinska Institutet Stockholm, Sweden.
出版信息
Eur Cardiol. 2023 Apr 18;18:e13. doi: 10.15420/ecr.2022.57. eCollection 2023.
Abstract
摘要
相似文献
1
Present and Future Perspectives on the Role of Biomarkers in Atherosclerotic Cardiovascular Disease Risk Stratification.生物标志物在动脉粥样硬化性心血管疾病风险分层中的作用：现状与未来展望
Eur Cardiol. 2023 Apr 18;18:e13. doi: 10.15420/ecr.2022.57. eCollection 2023.
2
Approach to risk stratification of atherosclerotic cardiovascular disease: Use of biomarkers and imaging in a Canadian context.动脉粥样硬化性心血管疾病风险分层方法：加拿大语境下的生物标志物和影像学的应用。
Can Fam Physician. 2022 Sep;68(9):654-660. doi: 10.46747/cfp.6809654.
3
Inflammation and Cardiovascular Disease: The Future.炎症与心血管疾病：未来展望
Eur Cardiol. 2021 May 17;16:e20. doi: 10.15420/ecr.2020.50. eCollection 2021 Feb.
4
Plasma Ceramides in Cardiovascular Disease Risk Stratification.血浆神经酰胺与心血管疾病风险分层。
Arq Bras Cardiol. 2022 Apr;118(4):768-777. doi: 10.36660/abc.20201165.
5
Cardiovascular Risk Stratification in Diabetic Retinopathy via Atherosclerotic Pathway in COVID-19/Non-COVID-19 Frameworks Using Artificial Intelligence Paradigm: A Narrative Review.在COVID-19/非COVID-19框架下通过人工智能范式的动脉粥样硬化途径对糖尿病视网膜病变进行心血管风险分层：一项叙述性综述
Diagnostics (Basel). 2022 May 14;12(5):1234. doi: 10.3390/diagnostics12051234.
6
Atherosclerotic Cardiovascular Risk Stratification in the Rheumatic Diseases:: An Integrative, Multiparametric Approach.风湿性疾病的动脉粥样硬化心血管风险分层：一种综合的、多参数的方法。
Rheum Dis Clin North Am. 2023 Feb;49(1):19-43. doi: 10.1016/j.rdc.2022.07.004.
7
Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors.神经酰胺除了改善标准风险因素外，还能改善动脉粥样硬化性心血管疾病的风险评估。
Clin Chim Acta. 2020 Dec;511:138-142. doi: 10.1016/j.cca.2020.10.005. Epub 2020 Oct 12.
8
[Coronary computed tomography: current role and future perspectives for cardiovascular risk stratification].
Monaldi Arch Chest Dis. 2011 Sep;76(3):115-20. doi: 10.4081/monaldi.2011.182.
9
Brachial-Ankle PWV: Current Status and Future Directions as a Useful Marker in the Management of Cardiovascular Disease and/or Cardiovascular Risk Factors.肱踝脉搏波速度：作为心血管疾病和/或心血管危险因素管理中有用标志物的现状与未来方向
J Atheroscler Thromb. 2016;23(2):128-46. doi: 10.5551/jat.32979. Epub 2015 Nov 11.
10
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.C反应蛋白及其他新兴血液生物标志物用于优化脆弱患者的风险分层。
J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C19-31. doi: 10.1016/j.jacc.2005.10.066.
引用本文的文献
1
A Multi-Biomarker Approach to Increase the Accuracy of Diagnosis and Management of Coronary Artery Disease.一种提高冠状动脉疾病诊断和管理准确性的多生物标志物方法。
J Cardiovasc Dev Dis. 2024 Aug 23;11(9):258. doi: 10.3390/jcdd11090258.
本文引用的文献
1
Artificial Intelligence and Cardiovascular Risk Prediction: All That Glitters is not Gold.人工智能与心血管风险预测：闪光的未必都是金子。
Eur Cardiol. 2022 Dec 20;17:e29. doi: 10.15420/ecr.2022.11. eCollection 2022 Feb.
2
Circulating Biomarkers in Lower Extremity Artery Disease.下肢动脉疾病中的循环生物标志物
Eur Cardiol. 2022 Mar 23;17:e09. doi: 10.15420/ecr.2021.58. eCollection 2022 Feb.
3
Circulating MicroRNAs as Novel Biomarkers in Risk Assessment and Prognosis of Coronary Artery Disease.循环微小RNA作为冠状动脉疾病风险评估和预后的新型生物标志物
Eur Cardiol. 2022 Mar 7;17:e06. doi: 10.15420/ecr.2021.47. eCollection 2022 Feb.
4
Epidemiology of cardiovascular disease in Europe.欧洲心血管疾病的流行病学。
Nat Rev Cardiol. 2022 Feb;19(2):133-143. doi: 10.1038/s41569-021-00607-3. Epub 2021 Sep 8.
5
Mendelian Randomization Analysis of Hemostatic Factors and Their Contribution to Peripheral Artery Disease-Brief Report.基于止血因子的孟德尔随机化分析及其对外周动脉疾病的影响——简短报告
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):380-386. doi: 10.1161/ATVBAHA.119.313847. Epub 2020 Aug 27.
6
Rivaroxaban in Peripheral Artery Disease after Revascularization.利伐沙班治疗血管重建术后外周动脉疾病
N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28.
7
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.主要肢体不良事件和外周动脉疾病患者的死亡率：COMPASS 试验。
J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11.
8
Specific miRNA Disease Biomarkers in Blood, Serum and Plasma: Challenges and Prospects.血液、血清和血浆中的特定miRNA疾病生物标志物：挑战与前景
Mol Diagn Ther. 2016 Dec;20(6):509-518. doi: 10.1007/s40291-016-0221-4.
9
Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians.评估心血管风险的现有评分的价值与局限性：临床医生综述
J Am Coll Cardiol. 2009 Sep 29;54(14):1209-27. doi: 10.1016/j.jacc.2009.07.020.
Zotero 插件